NCT02625961
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 102 versions: 46 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 13, 2026 Show 6 more changesShow less
- Eligibility criteria expanded, about 24 words
- Primary endpoints revised (4)
- Interventions: Favezelimab/pembrolizumab coformulation (Biological), Pembrolizumab (Biological), Pembrolizumab/vibostolimab coformulation (Biological) to Favezelimab/pembrolizumab coformulation (Biological), Pembrolizumab (Biological), Pembrolizumab/vibostolimab coformulation (Biological)
- Secondary endpoints: 8 to 49
- Publications: details revised at 2 of 2 entries
- Study arms: 2 to 4
- Notable Trial status: Completed to Terminated
- Sponsor's reason: Business Reasons
- Minor Trial status: Active, Not Recruiting to Completed
- Enrollment target: estimated 320 to confirmed 296
- Primary and study completion dates changed from estimate of Nov 15, 2025 to Nov 5, 2025
- Minor Primary and study completion dates: Oct 31, 2025 to Nov 15, 2025v99
- Minor Primary and study completion dates moved earlier to Oct 31, 2025v98
Show 41 earlier versionsHide 41 earlier versions
- Notable Primary endpoints: 5 to 4
- Secondary endpoints: 11 to 8
- Study description expanded, about 19 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 25 to 0
- Minor Study sites: 26 to 25v94
- Minor Study sites: 25 to 26v92
- Minor Study sites: 24 to 25v91
- Minor Study sites: 23 to 24v90
- Minor Study sites: 24 to 23v89
- Minor Study sites: 22 to 24v88
- Notable Primary endpoints: 3 to 5
- Secondary endpoints: 1 to 11
- Minor Study sites: 21 to 22v86
- Minor Study sites: 20 to 21v85
- Minor Site details revised at 1 of 20 sitesv84
- Minor Site details revised at 1 of 20 sitesv83
- Minor Study sites: 19 to 20v82
- Minor Site details revised at 1 of 19 sitesv81
- Minor Site details revised at 1 of 19 sitesv80
- Minor Study sites: 18 to 19v79
- Notable Eligibility criteria revisedv78
- Minor Study sites: 17 to 18v76
- Minor Study sites: 15 to 17v75
- Minor Study sites: 14 to 15v74
- Minor Study sites: 13 to 14v73
- Notable Eligibility criteria revisedv72
- Minor Study sites revised (13)v71
- Minor Site details revised at 1 of 13 sitesv70
- Minor Study sites revised (13)v69
- Notable Trial status: Active, Not Recruiting to Recruiting
- Study sites: 0 to 13
Notable Primary completion date: Jul 26, 2022 to Aug 30, 2026v67 Show 7 more changesShow less
- Primary endpoints: 2 to 3
- Eligibility criteria expanded, about 4 words
- Enrollment target: 260 to 320
- Study completion date: Jul 30, 2023 to Aug 31, 2030
- Interventions: pembrolizumab (Biological) to Favezelimab/pembrolizumab coformulation (Biological), Pembrolizumab (Biological), Pembrolizumab/vibostolimab coformulation (Biological)
- Study title expanded, about 6 words
- Study arms: 1 to 2
- Minor Primary completion date: Jun 15, 2022 to Jul 26, 2022v66
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 27 to 0
- Minor Study sites: 29 to 27v64
- Minor Study sites: 30 to 29v63
- Minor Site details revised at 1 of 30 sitesv62
- Minor Site contacts updated at 1 of 30 sitesv60
- Minor Site contacts updated at 1 of 30 sitesv59
- Minor Site contacts updated at 1 of 30 sitesv58
- Minor Site details revised at 1 of 30 sitesv57
- Minor Study sites: 32 to 30v56
- Minor Study sites: 34 to 32v55
- Minor Study sites: 35 to 34v54
- Minor Study sites: 36 to 35v53
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (49)
Show 44 moreShow less
Arms and interventions
Participants with carcinoma-in-situ (CIS) with or without papillary tumors will receive pembrolizumab, 200 mg, intravenously, every 3 weeks (Q3W) for up to 24 months.
Participants with papillary tumors only, without CIS will receive pembrolizumab, 200 mg, intravenously, Q3W for up to 24 months.
Participants with CIS with or without papillary tumors will receive pembrolizumab/vibostolimab coformulation intravenously Q3W for up to 24 months.
Participants with CIS with or without papillary tumors will receive favezelimab/pembrolizumab coformulation intravenously Q3W for up to 24 months.
Biologicals: Pembrolizumab, Pembrolizumab/vibostolimab coformulation, Favezelimab/pembrolizumab coformulation